Clinical Trial Update: Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric Cancer [Phase 2]

View source ↗

Summary

A completed Phase 2 dose-ranging trial assessed the antibody response to the G17DT vaccine in patients with gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• G17DT

Snippet

Sponsor: Cancer Advances Inc. | Conditions: Gastric Cancer | Phase 2 | Status: COMPLETED